TB-500

TB-500 (Thymosin Beta-4 fragment) is a peptide fragment (7 amino acids). The HEIVE catalog describes it as: An actin-binding fragment associated with cell migration and blood-vessel formation in injured tissue. It is also known as TB4, Thymosin beta-4 and TB 500.

HEIVE groups TB-500 under inflammation, tissue repair, training recovery, nerve repair and endurance. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for TB-500 under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval.

• FDA product data (October 6, 2026)
• FDA compounding safety information

The HEIVE editorial risk summary for TB-500 lists: Transient fatigue in the loading fortnight; injection-site swelling. Longer-term concerns: Angiogenesis is not selective. Anyone with an undiagnosed tumour is taking a real risk. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

TB-500 has no single onset time established by this catalog. The editorial timeline starts with “Days 1–7”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for TB-500: 2–2.5 mg twice weekly for 4 weeks, then weekly. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies TB-500 as mainly preclinical. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists a nasal form for TB-500. A listed form is not evidence of an approved or effective treatment. Nasal forms are listed in the source catalog; this does not establish approval, efficacy or equivalent absorption. HEIVE injection calculations do not apply to nasal forms.

Preparation of TB-500 depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for TB-500 depends on the specific formulation (injectable and nasal in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for TB-500: Loading then maintenance is standard; no withdrawal described. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

TB-500 and BPC-157 share the catalog categories inflammation, tissue repair and training recovery. TB-500: An actin-binding fragment associated with cell migration and blood-vessel formation in injured tissue. BPC-157: A synthetic fragment of a protein found in human gastric juice, studied almost entirely in rodents for accelerated soft-tissue healing. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View BPC-157

The HEIVE editorial summary highlights: Cardiac tissue studies showed vessel formation well outside the injured area. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.